From a digital hypothesis to verified biological reality

A closed biotechnology Design–Build–Test–Learn cycle—with method validation and evidence governance—without requiring each user to own or operate a laboratory.

Live now: A working online product with written project onboarding.

DOCUMENT ID	VERSION · DATE · LANGUAGE
DS-PUB-PDF-VISION-EN-20260812-R02	**DS-PUB-PDF-VISION-EN-20260812-R02 · 12 AUGUST 2026 · ENGLISH**

BRAND	BUYER CATEGORY
Due Science	**Independent Experimental Diligence for Biotech Transactions**
INVESTOR CATEGORY	**LONG-TERM CATEGORY**
AI-Native Evidence Infrastructure for Life-Science Transactions — infrastructure designed from the outset around artificial intelligence (AI)	**Biotech Verification-as-a-Service**
PRODUCT	**TECHNOLOGY**
Evidence Docket (versioned evidence record) · planned lifecycle layer: Evidence Passport	**Artificial-intelligence-assisted orchestration · expert governance · independent laboratory execution**

Toward creating and testing biotechnology without owning laboratory infrastructure.

Like cloud infrastructure makes it possible to run software without owning servers, Due Science aims to make it possible to create and test biotechnology without owning a laboratory or directly operating its equipment.

Artificial intelligence (AI), including specialised scientific models and large language models (LLMs), is expanding the range of molecules, proteins, protocols and biological hypotheses that people can design in a digital environment.

AI-assisted software development becomes productive when generated code can be executed, tested and inspected. Independent testing agents and an orchestration harness turn each result into the next development cycle. Actual execution remains the common reference point.

Biotechnology is moving toward a similar operating model. Digital design can propose a candidate. Physical biology determines how that candidate behaves. The next infrastructure opportunity is a traceable connection between those two environments.

- **Verification:** asks whether an experiment supports a specific claim.
- **Validation:** establishes whether the method can consistently measure the intended property.

Generation is scaling. Governed experimental learning can scale with it.

01

AI expands the design space

Scientific models can assist with protein sequence, structure, function, experimental design and interpretation.

02

Robotic laboratories structure execution

Automated workflows can produce instrument files, images, plate-level data, timestamps and run metadata in consistent digital formats.

03

Biotech decisions need bounded evidence

An investment, licence, option, financing tranche or portfolio milestone may depend on one carefully scoped experiment.

Design–Build–Test–Learn, with validation and evidence governance.

Design–Build–Test–Learn (DBTL) is the recurring cycle used in engineering biology. Due Science is designed to connect each stage through one traceable evidence record.

- **D · Design.** A person or specialised model formulates a hypothesis and a digital candidate.
- **B · Build.** An external laboratory converts the design into physical material or a cellular test article.
- **T · Test.** A prespecified robotic workflow executes the experiment with defined controls and repeats.
- **V · Validate.** The method, raw instrument data, execution record, deviations and analysis are reviewed against agreed criteria.
- **L · Learn.** The structured result returns to the digital environment and informs the next candidate or experiment.

The objective is a shorter, more accessible and more reproducible path from hypothesis to physical learning.

Independent Experimental Diligence for Biotech Transactions

Due Science is a live online service for buyers who need to test one scientific claim before an investment, licensing or portfolio decision. A buyer can assess testability, obtain a preliminary cost-and-time range, create a versioned Claim Brief and open the written project workflow online. For a commissioned project, Due Science converts the decision question into a locked experiment, confirms the independent robotic-laboratory route, coordinates physical execution and assembles the result into a versioned Evidence Docket.

The current standardized scope covers regenerative medicine and longevity: compact proteins such as cytokines—proteins that signal between cells—growth factors, enzymes and peptides, together with robotic measurements of repair-associated, resilience and inflammation-related cellular phenotypes (observable cell characteristics).

- **01 · Decision Question.** Define the claim, decision owner, deadline and available material.
- **02 · Verification Design Lock.** Fix the primary measurement, controls, repeats, result threshold and permitted interpretation before execution.
- **03 · Laboratory Routing.** Compare compatible sites by technical fit, total cost, timing, data rights and contract terms.
- **04 · Physical Execution and Review.** Collect raw instrument data and execution records, followed by accountable scientific and statistical review.
- **05 · Evidence Docket.** Deliver the protocol, documented data origin and handling history, deviations, data, analysis and a conclusion limited to the prespecified claim as one versioned record.

Physical execution begins after documented qualification of the specific laboratory site and workflow version, agreement of the scope and price, and execution of the applicable contracts. Due Science then uses the internal Qualified Robotic Laboratory (QRL) designation for that site-and-workflow combination; the designation is distinct from regulatory accreditation.

A working online product with written project onboarding.

Due Science is open for experimental-diligence projects. The live product provides an online testability assessment, preliminary cost-and-timeline planning, a structured Claim Brief and a versioned Draft Evidence Passport. Independent robotic-laboratory routes in the United States, Europe and Asia are evaluated within the written project workflow.

Online testability assessment → Cost-and-timeline planning range → Versioned Claim Brief and Draft Evidence Passport → Paid Verification Design Lock → Qualified robotic-laboratory execution and final Evidence Docket

The online assessment, record creation and written intake are live. Physical execution and final commercial terms are activated for each commissioned project after site-and-workflow qualification, quotation and contracting.

One verification. A reusable evidence lifecycle. A platform category.

- **01 · Evidence Docket — Commissioning open.** The versioned record of one verification: claim, protocol, criteria, sample and data provenance, execution metadata, deviations, raw instrument data, analysis and conclusion boundaries.
- **02 · Evidence Passport — Live intake and versioning layer.** Today it creates the controlled Draft record for an assessment and Claim Brief. The planned lifecycle extension will connect successive Evidence Dockets, authorised access, disclosures, reliance rights, milestones and repeat tests.
- **03 · Biotech Verification-as-a-Service — Long-term category.** Programmatic access to distributed robotic workflows for people, biotechnology teams and scientific agent systems—artificial-intelligence systems that can use tools and carry out research tasks.

Make each well-documented learning cycle easier to repeat.

The central economic unit is the cost and time of one well-documented learning cycle. Reusable experimental templates, controls, contracts, data formats and laboratory routing can make repeated testing progressively easier.

Both supportive and non-supportive results become structured knowledge. Teams can explore more candidates, confirm the strongest findings and direct resources using observed biological evidence.

A clear interface can also broaden participation. Clinicians, chemists, engineers, data scientists, computational biologists, disease foundations and entrepreneurs can formulate a question in the language of their field while the platform translates it into a governed experimental workflow.

Evidence infrastructure for individualized medicine.

Precision medicine selects treatment using patient characteristics. An individualized, or N-of-1, therapy is developed for one person or a very small group.

Over time, the same architecture may support a Patient-Specific Evidence Docket covering identity, purity, manufacturing quality, functional activity, relevant risk indicators and provenance for a particular therapeutic version.

This is a future regulated pathway, distinct from the current transaction-diligence service. It would operate through licensed clinical laboratories and healthcare partners, with jurisdiction-specific privacy, consent, quality, regulatory and medical governance. A Patient-Specific Evidence Docket would contribute structured evidence within that wider system; clinical safety and effectiveness would remain determined through regulated development, clinical evidence, regulatory review and licensed-clinician judgment.

The operating standard is designed to govern evidence before, during and after execution.

- Hypotheses, controls and acceptance criteria are fixed before execution.
- Funding and potential conflicts are disclosed; fees are independent of experimental outcome.
- Samples, native data, instrument records, manual actions, deviations and analytical versions remain traceable.
- Scientific, statistical, legal, medical and biosafety expertise enters at defined governance points.
- Laboratory qualification is specific to the site, method and workflow version.

Help shape the evidence layer for AI-native biotechnology.

We welcome concise written feedback from life-science funds, venture studios, diligence teams, biotechnology and pharmaceutical licensing professionals, robotic laboratories and scientific experts.

- Which buyer has the clearest need?
- Which bounded experiment could change a decision?
- What would make its Evidence Docket credible and reusable?

CONTINUE ONLINE · FIRST-PARTY LINKS

Open the current version	Start the online testability assessment	Share written feedback
duescience.com/r/pdf-vision-en-r02-current	duescience.com/r/pdf-vision-en-r02-assessment	duescience.com/r/pdf-vision-en-r02-feedback